Irinotecan hydrochloride Injection 100 mg in 5 mL (10)

Nchi: Australia

Lugha: Kiingereza

Chanzo: Department of Health (Therapeutic Goods Administration)

Viambatanisho vya kazi:

irinotecan hydrochloride trihydrate, Quantity: 20 mg/mL

Inapatikana kutoka:

Pfizer (Perth) Pty Ltd

Dawa fomu:

Injection, concentrated

Tungo:

Excipient Ingredients: sorbitol; water for injections; lactic acid

Njia ya uendeshaji:

Intravenous

Vitengo katika mfuko:

1 X 5 mL

Dawa ya aina:

(S1) This Schedule is intentionally blank

Matibabu dalili:

Irinotecan is indicated for single-agent or combination treatment of patients with: ? Metastatic carcinoma of the colon or rectum that has recurred or progressed following 5-fluorouracil (5-FU)-based therapy ? Irinotecan in combination with cetuximab is indicated for the treatment of patients with epidermal growth receptor (EGFR)-expressing metastatic colorectal cancer after failure of irinotecan-including cytotoxic therapy. ? Previously untreated metastatic carcinoma of the colon or rectum ? Advanced cervical squamous cell carcinoma ? Irinotecan in combination with 5-FU, folinic acid (FA) and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Bidhaa muhtasari:

Visual Identification: Clear, light yellow solution, free from visible particles.; Container Type: Vial; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Idhini hali ya:

Listed (Export Only)

Idhini ya tarehe:

2019-09-03